{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:14:36Z","timestamp":1788333276973,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We conducted the first multicentre Spanish real-world study assessing the efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic patients treated in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multicentre observational study included oligometastatic patients with primary solid tumours treated with SBRT between 2020 and 2024 across 12 Spanish radiotherapy centres. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall survival (OS), local control (LC), and acute and late adverse events by CTCAE v.5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      300 patients with 451 treated lesions were included. Median age was 69\u00a0years. After a median follow-up of 22\u00a0months, 1- and 2-year PFS were 45.1% and 36.3% respectively, with a median PFS of 11\u00a0months (95% CI, 9\u201313). The\u00a01- and 2-year OS were 92% and 82.9% (median not reached), and 1- and 2-year LC were 90.5% and 85.5% respectively. Multivariable analyses showed significantly better PFS and OS in prostate cancer patients. Repeat and induced oligometastatic patients showed worse PFS than those with synchronous disease (HR 2.86, 95% CI 1.59\u20135.13;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001 and HR 2.97, 95% CI 1.58\u20135.57;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001, respectively). Visceral-only disease also correlated with worse PFS compared to bone-only metastases. Local control was poorer in lesions \u22655\u00a0cm compared to &lt;5\u00a0cm\u00a0(\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). Grade \u22653\u00a0acute and late adverse events occurred in 0.7% and 1% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world multicentre cohort, SBRT to the oligometastases showed efficacy with minimal adverse events. Prognostic differences among subgroups underscore the importance of an adequate patient selection and individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04557-5","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:36:50Z","timestamp":1788331010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of stereotactic body radiotherapy in oligometastatic disease: a national real-world cohort study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1719-622X","authenticated-orcid":false,"given":"Macarena","family":"Teja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel J.","family":"Thuissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahams","family":"Ocanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Castalia","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisselott","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Escarlata","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Aakki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Begara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigfredo Elias","family":"Romero Zoghbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Andreescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Bezares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Gonz\u00e1lez del Portillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Holgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"1","key":"4557_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"key":"4557_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003.","journal-title":"Radiother Oncol"},{"issue":"4","key":"4557_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4143\/crt.2022.329","volume":"54","author":"CH Rim","year":"2022","unstructured":"Rim CH, Cho WK, Lee JH, Kim YS, Suh YG, Kim KH, et al. Role of local treatment for oligometastasis: a comparability-based meta-analysis. Cancer Res Treat. 2022;54(4):953\u201369. https:\/\/doi.org\/10.4143\/crt.2022.329.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"4557_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","volume":"196","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R, et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol. 2020;196(5):417\u201320. https:\/\/doi.org\/10.1007\/s00066-020-01603-1.","journal-title":"Strahlenther Onkol"},{"issue":"10185","key":"4557_CR5","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet"},{"key":"4557_CR6","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4557_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys. 2022;114(4):611\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"4557_CR8","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(16)30532-0.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4557_CR9","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","journal-title":"JAMA Oncol"},{"issue":"18","key":"4557_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4557_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"XS Wang","year":"2023","unstructured":"Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. J Natl Cancer Inst. 2023;115(6):742\u20138. https:\/\/doi.org\/10.1093\/jnci\/djac015.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4557_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"key":"4557_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2017","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2017;36:446\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4557_CR14","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, de Souza NM, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1.","journal-title":"Lancet Oncol"},{"key":"4557_CR15","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1016\/s0167-8140(23)08702-9","volume":"182","author":"V Khoo","year":"2023","unstructured":"Khoo V, Kirby A, Ahmed M, Dewan M, Van As N, Franks K, et al. OC-0761 CORE: standard of care +\/- stereotactic body radiotherapy for oligometastases\u2014primary results. Radiother Oncol. 2023;182:S627. https:\/\/doi.org\/10.1016\/s0167-8140(23)08702-9.","journal-title":"Radiother Oncol"},{"issue":"10422","key":"4557_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3.","journal-title":"Lancet"},{"issue":"1","key":"4557_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","volume":"121","author":"D Schellenberg","year":"2025","unstructured":"Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, et al. Stereotactic ablative radiation for oligoprogressive cancers: results of the randomized phase 2 STOP trial. Int J Radiat Oncol Biol Phys. 2025;121(1):28\u201338. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.031.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4557_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","volume":"27","author":"C Tang","year":"2026","unstructured":"Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, et al. Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration. Lancet Oncol. 2026;27(2):181\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(25)00658-8.","journal-title":"Lancet Oncol"},{"issue":"29","key":"4557_CR19","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377\u201382. https:\/\/doi.org\/10.1200\/JCO.22.00644.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4557_CR20","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","volume":"32","author":"P Iyengar","year":"2014","unstructured":"Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32(34):3824\u201330. https:\/\/doi.org\/10.1200\/JCO.2014.56.7412.","journal-title":"J Clin Oncol"},{"key":"4557_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100126","author":"J Weiss","year":"2019","unstructured":"Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019. https:\/\/doi.org\/10.1016\/j.ctarc.2019.100126.","journal-title":"Cancer Treat Res Commun"},{"key":"4557_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","volume":"168","author":"J Willmann","year":"2022","unstructured":"Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. 2022;168:256\u201364. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.019.","journal-title":"Radiother Oncol"},{"issue":"5","key":"4557_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ijrobp.2022.08.026","volume":"114","author":"S Baker","year":"2022","unstructured":"Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, et al. Validation of the prognostic utility of ESTRO\/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys. 2022;114(5):849\u201355. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4557_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","volume":"7","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 2021;7(1):92\u2013106. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6146.","journal-title":"JAMA Oncol"},{"key":"4557_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110717","volume":"205","author":"TK Nguyen","year":"2025","unstructured":"Nguyen TK, Louie AV, Kotecha R, Saxena A, Zhang Y, Guckenberger M, et al. Stereotactic body radiotherapy for non-spine bone metastases: a meta-analysis and International Stereotactic Radiosurgery Society (ISRS) clinical practice guidelines. Radiother Oncol. 2025;205:110717. https:\/\/doi.org\/10.1016\/j.radonc.2025.110717.","journal-title":"Radiother Oncol"},{"issue":"2","key":"4557_CR26","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/j.prro.2024.09.011","volume":"15","author":"C Franzese","year":"2025","unstructured":"Franzese C, Louie AV, Kotecha R, Zhang Z, Guckenberger M, Kim MS, et al. Stereotactic body radiation therapy for liver metastases: systematic review and meta-analysis with International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines. Pract Radiat Oncol. 2025;15(2):e172\u201388. https:\/\/doi.org\/10.1016\/j.prro.2024.09.011.","journal-title":"Pract Radiat Oncol"},{"key":"4557_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107284","volume":"182","author":"M Mayinger","year":"2023","unstructured":"Mayinger M, Kotecha R, Sahgal A, Kim MS, Lo SS, Louie AV, et al. Stereotactic body radiotherapy for lung oligo-metastases: systematic review and International Stereotactic Radiosurgery Society Practice Guidelines. Lung Cancer. 2023;182:107284. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107284.","journal-title":"Lung Cancer"},{"issue":"12","key":"4557_CR28","doi-asserted-by":"publisher","first-page":"e2549685","DOI":"10.1001\/jamanetworkopen.2025.49685","volume":"8","author":"J Willmann","year":"2025","unstructured":"Willmann J, von Wachter C, Zehnder R, Dee EC, Chen H, Hendriks LEL, et al. Stereotactic body radiotherapy without systemic therapy for oligometastatic cancer: a systematic review and meta-analysis. JAMA Netw Open. 2025;8(12):e2549685. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.49685.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4557_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. https:\/\/doi.org\/10.1186\/s12885-019-5977-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"4557_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12904-024-01548-7","volume":"23","author":"DA Palma","year":"2024","unstructured":"Palma DA, Giuliani ME, Correa RJM, Schneiders FL, Harrow S, Guckenberger M, et al. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol. BMC Palliat Care. 2024;23(1):223. https:\/\/doi.org\/10.1186\/s12904-024-01548-7.","journal-title":"BMC Palliat Care"},{"key":"4557_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109966","volume":"190","author":"M Guckenberger","year":"2024","unstructured":"Guckenberger M, Andratschke N, Belka C, Bellut D, Cuccia F, Dahele M, et al. ESTRO clinical practice guideline: stereotactic body radiotherapy for spine metastases. Radiother Oncol. 2024;190:109966. https:\/\/doi.org\/10.1016\/j.radonc.2023.109966.","journal-title":"Radiother Oncol"},{"key":"4557_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ctro.2022.08.006","volume":"37","author":"F Vilotte","year":"2022","unstructured":"Vilotte F, Pasquier D, Blanchard P, Supiot S, Khalifa J, Schick U, et al. Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncologists) consensus using a national two-round modified Delphi survey. Clin Transl Radiat Oncol. 2022;37:33\u201340. https:\/\/doi.org\/10.1016\/j.ctro.2022.08.006.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"4557_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12094-021-02695-6","volume":"24","author":"F Lopez-Campos","year":"2022","unstructured":"Lopez-Campos F, Cacicedo J, Cou\u00f1ago F, Garc\u00eda R, Leaman-Alcibar O, Navarro-Martin A, et al. SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. Clin Transl Oncol. 2022;24(2):215\u201326. https:\/\/doi.org\/10.1007\/s12094-021-02695-6.","journal-title":"Clin Transl Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04557-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04557-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04557-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:36:52Z","timestamp":1788331012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04557-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":33,"alternative-id":["4557"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04557-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FLC: Sponsored Research (J&J, Astellas, Bayer), Consulting, advisory role (J&J, Astellas, Bayer, Recordati, Ipsen), Lectures and educational activities (J&J, Astellas, Bayer, Recordati, Ipsen, Accord), Travel, accomodarions, expenses (Astellas, J&J, Recordati, Bayer). FC: Sponsored Research (J&J, Recordati), Consulting, advisory role (J&J, AstraZeneca), Lectures and educational activities (J&J, Roche Farma, AstraZeneca, Astellas, Recordati, Ipsen, Accord, Bayer), Travel, accommodations, expenses (AstraZeneca, Astellas, J&J, Roche Farma, Recordati, Bayer). SS: funding grants (Varian Medical Systems, Bayer, Merck), Speaking and lecture fees (Varian Medical Systems, Merck, AstraZeneca, Roche), Board membership (American Society for Radiation Oncology).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of La Princesa University Hospital and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients prior to SBRT.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}